Loss, gain, or mutation of the TRPV2 gene have been reported in hematological tumors, including mantle cell lymphoma, multiple myeloma, Burkitt lymphoma, acute myeloid leukemia, and myelodysplastic syndrome [18, 19]. This evidence concerns the gene TRPV2 and plasma cell myeloma.